Experts want closer attention to plasmodium vivax parasite in the fight against malaria. The complete sequence of the vivax genome, now reported in the Nature journal, can help scientists unlock many secrets, it is hoped.
The full sequence and its analysis were a collaboration involving scientists from a dozen institutions and coordinated by the Institute of Genomic Research, part of the J. Craig Venter Institute in Rockville, Maryland.
P. vivax is responsible for at least 25 percent of the roughly 500 million cases of malaria worldwide and is the major cause of malaria outside Africa, mainly afflicting Asia and the Americas.
The parasite cannot be cultured in the laboratory and can only be grown in living monkeys, and hence the role of primate researchers.
Galinski says the complete genetic sequence of P. vivax has revealed unique genes that appear to be important for invading the host's cells and in evading the host's immune system. Unlike other malaria parasites such as P. falciparum, P. vivax can only invade reticulocytes, immature red blood cells.
Both P. vivax and P. falciparum are carried by mosquitoes and can cause fever, chills, headache, nausea and vomiting. P. falciparum's genomic sequence was published in 2002.
Compared with P. falciparum, P. vivax's ability to come back from dormancy in the liver, its faster development in the mosquito and the outdoor biting behavior of mosquitoes it prefers may make P. vivax more resilient to common control methods such as insecticide-treated nets, Galinski says.
She says knowing P. vivax's full set of genes could help scientists better understand the distinctive "hypnozoite" phase of its life cycle, when the parasite lays dormant in liver cells for months or years after initial infection.
"That's one of the areas we hope to crack, but it will only be possible by combining the new genetic information with experiments in living animals," she says.
The complete sequence of the P. vivax genome could help scientists look for new drugs and design vaccines. In the Nature paper, the authors analyzed P. vivax enzymes by computer to examine how easily resistance could develop against the antimalarial compounds artemisinin and atovaquone.
Despite the threat posed by P. vivax, Galinski notes that only two candidate vaccines and one drug against P. vivax are now in clinical trials, compared with 23 vaccine candidates and 13 drugs for P. falciparum.
She and Alberto Moreno, professor of infectious diseases at Emory and an researchers at Yerkes and Emory Vaccine Center, recently published studies of a P. vivax vaccine candidate. They showed that the vaccine effectively stimulated monkeys' immune systems to produce antibodies, which in laboratory tests could block proteins the parasites use to invade blood cells.
Galinski is also a co-author on a companion paper in the same issue of Nature describing the genome of the malaria parasite Plasmodium knowlesi, whose natural host is the Kra monkey but can also infect humans. Because a laboratory culture system for P. vivax is lacking, this related parasite will be important for future malaria research, she says.